Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics" but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly Report (Form 10-Q) for the period ended January 31, 1999.
Status: Development Stage Enterprise. The company is in the pre-clinical trial stage of product development and has not commenced principal operations. Products require further testing and FDA approval before marketing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 1999 | Nine Months Ended Jan 31, 1999 | Accumulated Since Inception |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(151,948) | $(617,013) | $(10,185,735) |
| Research & Development Expense | $42,173 | $99,795 | $3,019,227 |
| General & Administrative Expense | $117,507 | $525,221 | $7,096,368 |
| Cash and Cash Equivalents | $170,960 (as of Jan 31, 1999) | ||
| Working Capital | Deficit of $(302,511) | ||
| Total Liabilities | $620,124 | ||
| Stockholders' Equity (Deficit) | $(130,704) |
Material Changes vs. Prior Period
- Net Loss (9 Months): Decreased to $(617,013) from $(742,277) in the prior year. This improvement was driven by a $105,000 reduction in administrative expenses (partially due to the absence of a $180,000 stock issuance expense in the current period) and a $10,000 increase in other income from a forfeited stock subscription fee.
- Net Loss (3 Months): Increased slightly to $(151,948) from $(149,842). Total expenses rose by approximately $14,000 due to increased research supplies and a new California laboratory, offset by the aforementioned other income.
- Cash Position: Cash decreased from $740,215 (April 30, 1998) to $170,960 (January 31, 1999). Net cash used in operating activities was $(7,016,295) for the nine-month period, while financing activities provided $7,835,190.
- Debt: Current portion of notes payable increased from $59,972 to $138,576.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has accumulated losses of over $10 million and a working capital deficit.
- Capital Needs: Significant additional financing is required to complete pre-clinical testing and proceed to Phase I, II, and III human trials. Management is pursuing strategic alliances and joint ventures but has no firm commitments for additional funding as of January 31, 1999.
- Regulatory Risk: No assurance can be given that FDA approval will be granted once applied for.
- Recent Financing: During the period, the company issued 210,000 shares to third-party investors at $0.125 per share plus options, and 25,000 shares to a consultant for services.
- Contingencies: The company has employment agreements with future commitments of $271,000 through March 2001. No material litigation is currently pending.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured the necessary funding to bridge the gap to FDA approval, given the $302,511 working capital deficit and $170,960 cash balance.
- Dilution Risk: Assess the impact of future equity issuances required to fund operations, noting the recent issuance of stock for services and cash.
- Development Milestones: Confirm the status of pre-clinical trials and the timeline for FDA submission, as the business model relies entirely on regulatory approval.
- Debt Obligations: Review the terms of the notes payable (current portion $138,576) to understand immediate repayment pressures.